Updates on capivasertib, belzutifan, talquetamab, & durvalumab

Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion:…